Last updated: February 15, 2026
Overview
NDC 69238-1505 is identified as Cobicistat-Boosted Darunavir used in the treatment of HIV-1 infection. It combines darunavir, a protease inhibitor, with cobicistat, a pharmacokinetic enhancer. The drug, marketed under the brand name "Prezcobix" or "Rezolute," is indicated for adult and adolescent patients requiring combination antiretroviral therapy.
Market Landscape
The HIV treatment market is driven by ongoing demand for effective, tolerable therapies and competitive pressure from generics and new entrants.
-
Market Size: The global HIV drug market was valued at approximately $12.5 billion in 2022, with protease inhibitors accounting for around 20-25% of this total.
-
Key Competitors:
- Bristol-Myers Squibb's Daruvia (darunavir-based)
- Gilead Sciences’ Descovy and Truvada (NRTI-based)
- ViiV Healthcare’s Juluca and Dovato (integrated regimens, including protease inhibitors)
-
Market Penetration: The drug faces competition from generics of darunavir and other combination therapies. However, patents protect the brand formulations, giving exclusivity for approximately 10-12 years from approval.
Patent and Regulatory Status
- Approval date: December 24, 2014 (FDA)
- Patent expiry: Estimated around 2026-2028, depending on patent extensions and legal actions.
- Regulatory updates: Approved for both oral and pediatric formulations, with recent supplemental approvals for enhanced pediatric usage.
Pricing Trends
-
Current Price Point: As of 2023, wholesale acquisition cost (WAC) for brand-name Prezcobix approximates $2,500-$3,000 per month per patient.
-
Pricing Comparison:
- Generics: Darunavir standalone generics are priced around $1,000-$1,200 per month.
- Fixed-dose combinations: Marketed formulations range from $2,000 to $3,500 per month.
-
Pricing Drivers:
- Patent exclusivity prolongs premium pricing.
- Insurance coverage and patient assistance programs influence net prices.
- Emerging generic competition could reduce prices over the next 2-3 years.
Market Projections
-
Short Term (1-2 years):
- Maintains premium pricing due to patent protection.
- Sales volumes increase modestly with expanded indications and insurance coverage.
-
Medium Term (3-5 years):
- Price erosion expected as patent expirations approach.
- Entry of generic competitors could reduce brand price by 30-50%.
- Overall market growth limited by saturation in developed markets.
-
Long Term (5+ years):
- Potential price declines of 50-70% upon patent expiry.
- Market share shifts towards generics and new therapies with better tolerability or convenience.
Factors Influencing Future Pricing and Market Share
- Patent litigation outcomes.
- Development and approval of third-generation protease inhibitors or novel HIV agents.
- Changes in treatment guidelines favoring other drug classes.
- Global access initiatives, particularly in low- and middle-income countries.
- Cost pressures from healthcare systems and payers.
Conclusion
NDC 69238-1505 is positioned in a mature segment with established competition. Current pricing remains high due to patent protection, but significant price declines are anticipated once generics enter the market. The total market size will remain stable with incremental growth driven by expanding indications and improved treatment adherence.
Key Takeaways
- The drug commands a price of approximately $2,500-$3,000 per month in the US.
- Patent exclusivity is expected until 2026-2028.
- Generic entry forecasted to reduce prices by up to 50% over 2-3 years post-patent expiry.
- Market growth driven primarily by brand loyalty and remaning patent period; will contract with the advent of generics.
- Competitive landscape includes existing and emerging therapies in HIV management.
FAQs
-
What is the main competitor to NDC 69238-1505?
Darunavir monotherapy and other fixed-dose combination therapies like Darunavir/cobicistat generics.
-
When will patent expiration most likely occur?
Between 2026 and 2028, depending on patent extensions and legal challenges.
-
How will generics impact pricing?
Entering generics generally reduce prices by 30-50%, potentially more depending on market dynamics.
-
What are the primary factors influencing the market in emerging countries?
Patent restrictions, pricing policies, and access programs.
-
Are new drugs likely to replace NDC 69238-1505?
Future competition may come from newer treatments with improved safety profiles, but current best practices favor protease inhibitor-based regimens.
Citations
[1] IQVIA, "The Market for HIV Antiretroviral Drugs," 2023
[2] FDA, "Drug Approval Package," December 2014
[3] EvaluatePharma, "HIV Market Forecast," 2022
[4] Medscape, "HIV Treatment Cost Comparison," 2023
[5] U.S. Patent Office, "Patent Expiry Data," 2023
